Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium
Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium
Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus
Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…Abstract Number: 113 • 2020 Pediatric Rheumatology Symposium
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
Background/Purpose: Rituximab is standard therapy in treating autoimmune brain disease (ABD) including refractory autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing…Abstract Number: 143 • 2020 Pediatric Rheumatology Symposium
Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease
Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), and Autoimmune Encephallitis (AE) arise due to dysregulation of the immune system and a…Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients
Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting
The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…Abstract Number: 309 • 2019 ACR/ARP Annual Meeting
Increasing Capacity and Reducing Costs of Rituximab Administration
Background/Purpose: Rituximab (RTX) is associated with a large cost burden on the healthcare system and treatment delays that often exceed one month because the long…Abstract Number: 383 • 2019 ACR/ARP Annual Meeting
Retroperitoneal Fibrosis- a Single Center Experience
Background/Purpose: Idiopathic retroperitoneal fibrosis (iRPF) is a rare, chronic, progressive disorder of unknown etiology and characterized by the presence of inflammatory and fibrous retroperitoneal tissue…Abstract Number: 537 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…Abstract Number: 539 • 2019 ACR/ARP Annual Meeting
A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Background/Purpose: ABP 798 is being developed as a biosimilar to rituximab, a CD20-directed cytolytic antibody that is approved in the US and EU for treatment…Abstract Number: 793 • 2019 ACR/ARP Annual Meeting
Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients
Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare multi-systemic disease characterized by fibrous changes of the skin and internal organs [1]. Patients with “rapidly progressive”…Abstract Number: 806 • 2019 ACR/ARP Annual Meeting
A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and relapse rates…Abstract Number: 845 • 2019 ACR/ARP Annual Meeting
Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions
Background/Purpose: Rituximab (RTX) is used in a wide variety of rheumatic disease. Emerging guidelines suggest measuring immunoglobulins (Ig) at pre-treatment screening and prior to repeat…Abstract Number: 882 • 2019 ACR/ARP Annual Meeting
Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis
Background/Purpose: Tubulointerstitial inflammation (TII) in lupus nephritis (LN) is associated with a worse prognosis. Vimentin, a cytoplasmic antigen, is commonly targeted by in situ activated…
ACR Meeting Abstracts